You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
研發防疫藥品公司有追捧 石四藥(02005.HK)漲近3% 中國醫療(08225.HK)飆升2.2倍
阿思達克 01-29 11:31
國家衛健委公布截至午夜,內地新型冠狀病毒感染肺炎續增至5,978宗,死亡人數增至132人。研發相關應對產品個別醫藥股今早見有追捧,石四藥(02005.HK)抗病毒藥物阿比多爾膠囊已准入18個省份防控疫情產品儲備目錄或防控藥品綠色通道,另有11個省份即將按此方式完成准入工作,股價兩連漲,今早高見8.4元,新造8.03元,升2.7%,成交1,253萬股,涉資1億元。 展開新型冠狀病毒藥品研究的中國醫療集團(08225.HK)飆升逾2倍高見0.395元,創逾年半高,現造0.36元,飆升2.2倍,成交激增至5,006萬股,創近兩年高,涉資1,595萬元。 石四藥集團公布,為新型冠狀病毒感染的疫情防控工作,中國各省市開通了首批相關防控藥品直接掛網採購綠色通道,或者將相關防控藥品直接納入應急採購範圍。而集團抗病毒藥物阿比多爾膠囊已准入18個省份防控疫情產品儲備目錄或防控藥品綠色通道,另有11個省份即將按此方式完成准入工作。 中國醫療表示,抗擊冠狀病毒藥品臨床大數據篩選中心,新型冠狀病毒感染肺炎疫情暴發,集團成立數字臨床研究專項行動組,由在抗擊Sars疫情中從事臨床研究的宋雪梅博士牽頭,與北京大學協和醫學院和武漢同濟大學專家篩選戰勝這次疫情的藥品和開展相應RWS研究。 另邊廂,獲藥藍局批准於內地進行ASC22對慢性乙型肝炎患者臨床試驗的歌禮製藥(01672.HK)今天復市股價逆市飆升高見4.6元,現造4.23元,飆升42%,成交激增至3,974萬股,創近年半高,涉資1.55億元。 歌禮製藥上周四公布,公司已獲得藥監局批准,於中國進行ASC22對慢性乙型肝炎患者的臨床試驗。ASC22為獲蘇州康寧傑瑞生物科技許可同類首創皮下注射PD-L1抗體,公司相信,由於慢性乙型肝炎病毒感染中T細胞衰竭為影響免疫耐受性重要因素,因此阻斷PD-1/PD-L1路徑或為改善特定T細胞功能並實現慢性乙型肝炎臨床治癒的有效免疫療法。除ASC22外,公司仍有其他三種用於治療慢性乙型肝炎的藥品或在研藥物,即市售藥品Pegasys及兩種內部研發的臨床實驗前或待臨床實驗在研藥物。(sz/t)~ 阿思達克財經新聞 網址: www.aastocks.com
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account